ProCE Banner Activity

KEYNOTE-564: Updated Analysis of a Phase III Trial of Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Clear Cell Renal Cell Carcinoma

Conference Coverage

The third interim analysis of the phase III KEYNOTE-564 trial demonstrated that adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma who are at increased risk of recurrence following surgery.

Released: February 02, 2024


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC